Madelaine Sgroi, DO
Hematology & Oncology · Brunswick, MENPI 1184835951
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations.
Across 138 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$322
- E.r. Squibb & Sons, L.L.C.$287
- Bristol Myers Squibb$251
- Merck$172
- Eisai Inc.$161
- Johnson & Johnson$126
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,59897%
- Education$873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $322 |
| E.r. Squibb & Sons, L.L.C. | 12 | $287 |
| Bristol Myers Squibb | 7 | $251 |
| Merck | 9 | $172 |
| Eisai Inc. | 9 | $161 |
| Johnson & Johnson | 7 | $126 |
| Amgen | 7 | $120 |
| Genentech USA, Inc. | 9 | $120 |
| Seagen Inc. | 7 | $120 |
| AstraZeneca | 6 | $98 |
| Pfizer | 4 | $86 |
| Gilead | 4 | $75 |
| Array Biopharma Inc | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Sanofi | 2 | $48 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $47 |
| Beigene USA, Inc. | 2 | $47 |
| Pharmacosmos Therapeutics Inc. | 2 | $47 |
| Puma Biotechnology, Inc. | 2 | $36 |
| Pharmaessentia USA Corporation | 2 | $33 |
| GSK | 2 | $30 |
| Blueprint Medicines Corporation | 1 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Exelixis Inc. | 1 | $27 |
| Partner Therapeutics, Inc. | 1 | $24 |
| Incyte Corporation | 2 | $23 |
| Genmab U.S., Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Deciphera Pharmaceuticals Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Iovance Biotherapeutics, Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Bayer | 1 | $14 |
| Veracyte, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Revlimid$125
How this compares
$2,685 in reported general payments places this provider in the 65th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 12 | $248,452 |
| TasignaNilotinib Hcl | 11 | $215,204 |
| RevlimidLenalidomide | 12 | $207,104 |
| JakafiRuxolitinib Phosphate | 15 | $149,142 |
| XareltoRivaroxaban | 12 | $6,908 |
| Abiraterone Acetate | 13 | $2,332 |
| Anastrozole | 114 | $1,760 |
| Dexamethasone | 21 | $495 |
| Acyclovir | 27 | $242 |
| Omeprazole | 26 | $152 |
| Ondansetron OdtOndansetron | 11 | $105 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna | $322 | $215,20411 claims |
| Bristol Myers SquibbRevlimid | $251 | $207,10412 claims |
| Incyte CorporationJakafi | $23 | $149,14215 claims |
| Johnson & JohnsonXarelto | $126 | $6,90812 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $27 | $2,33213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 60 hematology & oncology providers in Maine.
Other hematology & oncology in Brunswick
- Edgardo Ortiz FloresBrunswick$2K
- Helen YuanBrunswick$1K
- Hillary GlickBrunswick$215
- Allison SmithBrunswick$215
- Matthew DuganWestbrook$577K
- John WintersWestbrook$341K
- Helen RyanKennebunk$83K
- Eleni NackosWestbrook$79K
- Christian ThomasWestbrook$54K
- Devon EvansWestbrook$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.